Trent G. Kamke Sells 2,009 Shares of LeMaitre Vascular, Inc. (NASDAQ:LMAT) Stock

LeMaitre Vascular, Inc. (NASDAQ:LMAT) insider Trent G. Kamke sold 2,009 shares of the stock in a transaction dated Wednesday, March 12th. The stock was sold at an average price of $82.12, for a total transaction of $164,979.08. Following the sale, the insider now directly owns 5,564 shares in the company, valued at $456,915.68. This represents a 26.53 % decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through this link.

LeMaitre Vascular Stock Up 3.9 %

Shares of LeMaitre Vascular stock opened at $81.91 on Monday. The firm has a market capitalization of $1.85 billion, a P/E ratio of 44.76, a P/E/G ratio of 2.22 and a beta of 0.89. LeMaitre Vascular, Inc. has a 52 week low of $62.39 and a 52 week high of $109.58. The firm’s 50 day moving average is $95.21 and its two-hundred day moving average is $94.67.

LeMaitre Vascular (NASDAQ:LMAT) last announced its quarterly earnings results on Thursday, February 27th. The medical instruments supplier reported $0.49 EPS for the quarter, meeting the consensus estimate of $0.49. The company had revenue of $55.81 million for the quarter, compared to analyst estimates of $55.99 million. LeMaitre Vascular had a net margin of 19.40% and a return on equity of 13.15%. As a group, research analysts expect that LeMaitre Vascular, Inc. will post 1.94 earnings per share for the current fiscal year.

LeMaitre Vascular Increases Dividend

The firm also recently announced a quarterly dividend, which will be paid on Thursday, March 27th. Stockholders of record on Thursday, March 13th will be given a dividend of $0.20 per share. The ex-dividend date is Thursday, March 13th. This is a positive change from LeMaitre Vascular’s previous quarterly dividend of $0.16. This represents a $0.80 dividend on an annualized basis and a dividend yield of 0.98%. LeMaitre Vascular’s dividend payout ratio (DPR) is 41.24%.

Wall Street Analyst Weigh In

LMAT has been the topic of several research reports. Lake Street Capital increased their price target on shares of LeMaitre Vascular from $105.00 to $110.00 and gave the stock a “buy” rating in a research report on Friday, February 28th. Oppenheimer lowered shares of LeMaitre Vascular from an “outperform” rating to a “market perform” rating in a research note on Friday, February 28th. Wells Fargo & Company initiated coverage on shares of LeMaitre Vascular in a research note on Thursday, February 13th. They set an “equal weight” rating and a $95.00 target price on the stock. StockNews.com lowered shares of LeMaitre Vascular from a “buy” rating to a “hold” rating in a research note on Friday, December 13th. Finally, Barrington Research lowered shares of LeMaitre Vascular from an “outperform” rating to a “market perform” rating in a research note on Friday, February 28th. Five equities research analysts have rated the stock with a hold rating, four have issued a buy rating and one has given a strong buy rating to the company’s stock. According to data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $95.25.

Hedge Funds Weigh In On LeMaitre Vascular

Hedge funds have recently modified their holdings of the business. Allspring Global Investments Holdings LLC grew its position in shares of LeMaitre Vascular by 48.2% during the fourth quarter. Allspring Global Investments Holdings LLC now owns 13,321 shares of the medical instruments supplier’s stock worth $1,227,000 after acquiring an additional 4,330 shares during the last quarter. Townsquare Capital LLC grew its position in shares of LeMaitre Vascular by 38.0% during the third quarter. Townsquare Capital LLC now owns 47,953 shares of the medical instruments supplier’s stock worth $4,454,000 after acquiring an additional 13,210 shares during the last quarter. Barclays PLC grew its position in shares of LeMaitre Vascular by 394.5% during the third quarter. Barclays PLC now owns 36,577 shares of the medical instruments supplier’s stock worth $3,396,000 after acquiring an additional 29,180 shares during the last quarter. Compass Planning Associates Inc purchased a new position in shares of LeMaitre Vascular during the fourth quarter worth approximately $567,000. Finally, Charles Schwab Investment Management Inc. grew its position in shares of LeMaitre Vascular by 6.3% during the third quarter. Charles Schwab Investment Management Inc. now owns 191,511 shares of the medical instruments supplier’s stock worth $17,789,000 after acquiring an additional 11,395 shares during the last quarter. 84.64% of the stock is currently owned by hedge funds and other institutional investors.

About LeMaitre Vascular

LeMaitre Vascular, Inc develops, manufactures, and markets medical devices and implants used in the field of vascular surgery worldwide. It offers human cadaver tissue cryopreservation services; angioscope, a fiberoptic catheter used for viewing the lumen of a blood vessel; embolectomy catheters to remove blood clots from arteries; thrombectomy catheters for removing thrombi in the venous system; occlusion catheters that temporarily occlude the blood flow; and perfusion catheters to perfuse the blood and other fluids into the vasculature.